Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alk Abello A/S Maintains FY 2012 Financial Guidance


Monday, 12 Nov 2012 02:53am EST 

Alk Abello A/S announced that its EBITDA outlook for the fiscal year 2012 remains unchanged. The Company still expects fiscal year 2012 EBITDA to exceed DKK 300 million. Growth in vaccine sales for the fiscal year 2012 is now expected to be slightly positive in the range of between 0% and 2% (previously between 3% and 5%), measured in local currencies. Total revenue of up to DKK 2.4 billion is still expected for the fiscal year 2012 as revenues from partnerships largely will offset the lower than expected vaccine sales. According to I/B/E/S Estimates, analysts on average are expecting the Company to report fiscal year 2012 EBITDA of DKK 327.26 million and fiscal year 2012 revenue of DKK 2,379.34 million. 

Company Quote

716.0
-17.0 -2.32%
19 Sep 2014